Moderna's approach to vaccine patents worldwide; a massive Medicaid rebate settlement

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: Moderna will never enforce Covid-19 vaccine patents in poor countries By Ed Silverman Charles Krupa/AP Moderna will offer licenses for its technology to manufacturers on "commercially reasonable terms" for distribution in wealthy countries. Read More STAT+: Mallinckrodt to pay $260 million to settle federal lawsuits over Medicaid rebates and kickbacks By Ed Silverman AP Images for Mallinckrodt Mallinckrodt will pay $260 million to settle accusations that it underpaid Medicaid rebates and illegally used a charity to pay kickbacks. Read More STAT+: Congress moves toward giving FDA authority over synthetic nicotine products like Puff Bar By Nicholas Florko Marshall Ritzel/AP Lawmakers are within striking distance of closing the largest loophole in the FDA's oversight of e-cigarette companies. Read More Sponsor content by Guidehouse How can digital solutions assessment optimize clinical trials? The biopharmaceutical industry faces significant challenges related to clinical trials design and execution, including rising costs, difficulties with representative patient recruitment and retention as well as cumbersome trial design and management processes. These hurdles become pronounced when factors such as variable disease severity, therapeutic diversity, treatment access, and patient non-compliance are introduced. Confronted with these challenges, learn how organizations can optimize clinical trial programs and processes. Opinion: The U.S. must fix its innovation engine: the patent system By Adam Mossoff Adobe A 2014 Supreme Court ruling on patents hit the biotech sector particularly hard. Congress needs to modernize U.S. patent law. Read More STAT+: A glaring gap in Congress' surprise billing law leaves patients on the hook for pricey, out-of-network lab tests By Bob Herman Molly Ferguson Even though the lab was down the hall from his doctor, it was still out-of-network. A new law against surprise medical bills doesn’t fix it. Read More Tuesday, March 8, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser